CD279 (PD1) Antibody Kit, anti-mouse, APC, REAlease® from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for CD279 (PD1) Antibody Kit, anti-mouse, APC, REAlease® products.
| Edit | |
|---|---|
| Product Name | CD279 (PD1) Antibody Kit, anti-mouse, APC, REAlease® |
| Description | CD279 (PD1) Antibody Kit, anti-mouse, APC, REAlease®. Clone REAL269 is an antibody fragment derived from the full CD279 (PD1) antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity. | Clone REAL269 recognizes the mouse CD279 antigen, also known as PD1. CD279 is a member of the Ig superfamily expressed mainly on activated T and B lymphocytes. Expression is induced on activated myeloid cells as well. CD279 is thought to be involved in lymphocyte clonal selection and plays a key role in peripheral tolerance and autoimmune disease in mice. The ligands of CD279, PDL1 (B7-H1) and PDL2 (B7-DC), belong to the B7 immunoglobulin superfamily. | The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes. |
| Size | 100 tests |
| Concentration | 1:50 |
| Applications | Flow cytometry, MICS (MACSima Imaging Cyclic Staining), Immunofluorescence, Immunohistochemistry |
| Other Names | n/a |
| Gene, Accession, CAS # | n/a |
| Catalog # | 130-122-659 |
| Price | $162 |
| Order / More Info | CD279 (PD1) Antibody Kit, anti-mouse, APC, REAlease® from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Iwai, Y. et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U.S.A. 99: 12293-12297. | Salama, A. D. et al. (2003) Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 198: 71-78. | Hirano, F. et al. (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunitiy. Cancer Res. 65: 1089-1096. | Tsushima, F. et al. (2007) Interaction between B7-H1 and PD-1 determines initiation and reversal of T cell anergy. Blood 110: 180-185. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG